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Background. Transjugular liver biopsy (TJLB) is frequently used to obtain liver specimens in high-risk patients. However,
TJLB sample size possibly limits their clinical relevance. Methods. 102 patients that underwent TJLB were included. Clinical
parameters and outcome of TJLB were analyzed. Control samples consisted of 112 minilaparoscopic liver biopsies (mLLBs) and
100 percutaneous liver biopsies (PLBs). Results. Fewer portal tracts were detected in TJLB (4.3 ± 0.3) in comparison with PLB
(11.7±0.5) and mLLB (11.0±0.6). No diﬀerence regarding the speciﬁcation of indeterminate liver disease and staging/grading of
chronic hepatitis was observed. In acute liver failure (n = 32), a proportion of hepatocellular necrosis beyond 25% was associated
with a higher rate of death or liver transplantation. Conclusions. Despite smaller biopsy samples the impact on the clinical decision
process was found to be comparable to PLB and mLLB. TJLB represents a helpful tool to determine hepatocellular necrosis rates
in patients with acute liver failure.
Copyright © 2009 Max G. Beckmann et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Liver biopsy is regarded as the “gold standard” for the
evaluation of liver disorders and the most speciﬁc test to
assess the nature as well as the grading and staging of certain
liver diseases [1, 2].
Various clinical conditions require a diagnostic liver
biopsy. These include liver disease of unknown origin, acute
or subacute liver failure, cellular rejection in patients after
liver transplantation, or grading and staging of chronic
hepatitis.
Percutaneous liver biopsy (PLB), transjugular liver
biopsy(TJLB),andminilaparoscopicliverbiopsy(mLLB)are
most frequently applied techniques to obtain liver specimens
[3, 4].
PLB is usually used as the preferred method, because it is
an easy to perform, cost eﬃcient, and reliable method that
produces biopsy cylinders of up to 4cm. However ascites
and/or signiﬁcant coagulopathy preclude the utilization of
PLB due to the risk of severe hemorrhage [2, 4]. TJLB
is an alternative to PLB, because bleeding resulting from
the biopsy needle will drain into the hepatic veins. Other
indications for TJLB include massively adipose patients [5].
Transjugular liver biopsy (TJLB) was ﬁrst experimentally
applied in dogs in 1964 [6] and was introduced into
clinics in the early 1970s [7]. However, TJLB has been
considered to be less satisfactory in comparison with PLB
because the samples obtained are smaller and the cylinders
thinner owing to the limited size of the introducer set. The
introduction of true cut systems has improved the biopsy2 Gastroenterology Research and Practice
quality of TJLB in comparison with aspiration biopsies
[8–10].
Recently, mLLB has been more widely employed as an
alternative to TJLB in cases of coagulopathy and ascites
[4, 11]. In contrast to PLB and TJLB, mLLB also provides
macroscopic information on the liver surface in addition to
histopathology. This way mLLB can help to avoid sampling
errors. In addition bleeding from biopsy puncture sites can
be coagulated under direct vision.
The goal of this study was to elucidate the clinical
relevance of the TJLB with respect to speciﬁc clinical
indications (indeterminate liver disease, acute/subacute liver
failure, chronic hepatitis, and suspected graft rejection after
liver transplantation). Furthermore, the signiﬁcance of the
TJLB for the speciﬁc clinical problem was compared with
results from PLB and mLLB.
2.MaterialsandMethods
We identiﬁed all patients that underwent TJLB at the Han-
nover Medical School between January 2000 and October
2007. As controls we selected a cohort of 100 consecutive
patients that underwent PLB from 01/2007–06/2007. As a
third group, all patients that underwent mLLB in the period
04/2005–10/2007 served as controls.
Complete patient charts were available in electronic for-
mat. The following data were extracted. There is indication
for either PLB, TJLB, or mLLB. Indications were grouped as:
(1) diagnostic work up for liver disease of unknown
origin,
(2) Staging and grading of chronic hepatitis,
(3) diagnostic work up for acute/subacute liver failure,
(4) diagnostic work up of liver transplant (oLT) patients
with elevated liver function tests (LFTs),
(5) others, for example, cholestatic liver disease.
Contraindications for PLB were recorded: (i) presence of
ascites, (ii) coagulopathy (deﬁned as prothrombin time
>50% above normal and/or partial thromboplastin time >50
seconds and/or platelet count <50 103/μL), or (iii) presence
of ascites and coagulopathy. The technical feasibility as well
as the reasons for unsuccessful biopsy were extracted from
the biopsy protocols. Complications related to the biopsies
and clinical consequences were detected from the biopsy
protocols and by reviewing the patients’ charts.
To assess the quality of the biopsy specimen several
parameters were recorded including the number of nee-
dle passes, insuﬃcient biopsy material according to the
pathological report, and the number of complete portal
tracts. If the number of complete portal tracts was not
speciﬁed in the report, stored biopsy slides were re-evaluated
(M.G.Beckmann and M.Bredt).
To assess the impact of the biopsy on the clinical course
the pathology report and the discharge summary as well as
the long-term clinical course were reviewed (J.Wedemeyer).
For the group of patients that underwent biopsies to evaluate
idiopathic/cryptogenic liver disease we determined from
the patients’ charts whether a speciﬁc diagnosis could be
established or whether liver disease remained cryptogenic. If
aspeciﬁcdiagnosiswasestablished,weevaluatedwhetherthe
histological results from the biopsies either were relevant for
the establishment of the diagnosis or whether no speciﬁca-
tion was given in the histological report that supported the
ﬁnal diagnosis.
In the patients that underwent TJLB for staging/grading
of chronic hepatitis we checked the pathology reports
whether a histological staging/grading according to Ishak et
al. [12] was possible.
In the group of patients that were evaluated for
acute/subacute liver failure we additionally reviewed the
proportion of necrosis of the liver parenchyma. Necrosis was
grouped as follows: (1) no necrosis, (2) low necrosis (1%–
25%), (3) medium necrosis (26%–50%), (4) severe necrosis
(51%–75%), and (5) complete necrosis (76%–100%). If
necrosis was not quantiﬁed in the pathology report, stored
slides were reevaluated (M.Bredt). Additionally, we assessed
the clinical outcome in this patient group. Outcome was
categorized as (1) spontaneous recovery, (2) liver transplan-
tation, and (3) death.
2.1. Biopsy Procedures. All types of biopsy procedures were
carried out according to standardized protocols.
Most of the TJLB (n=99, 97%) and all mLLB were
performed under conscious sedation using midazolam and
disoprivan.Nosedationrelatedcomplicationswerereported.
The sedation was performed and controlled by the physi-
cians with support of the nursing staﬀ. In 3 cases TJLB
was performed in general anesthesia, because the patient
was already intubated due to progressive encephalopathy
and/or respiratory failure before the decision to perform
transjugular liver biopsy was made.
Blood pressure, heart rate, and oxygen saturation were
monitored noninvasively. For TJLB continuous ECG moni-
toring was used.
TJLBwasperformedviatherightjugularvein.Afterlocal
anaesthesia and puncture of the right jugular vein a 0.89mm
diameter Terumo guide wire (Terumo, Eschborn, Germany)
was inserted. In all TJLB procedures, an 18G Quick—Core
biopsy set (true cut system, Cook Medical, Denmark) was
used, which was introduced via the guide wire. Correct
positioning of the biopsy set was veriﬁed by ﬂuoroscopy. In
2006, ultrasonography of the jugular vein before puncture
was implemented in the routine protocol.
Forpercutaneousbiopsythepositionanddirectionofthe
biopsy tract were deﬁned under ultrasound control. Five mL
xylocaine(1%)wasusedaslocalanesthesia.Allbiopsieswere
performed using a Menghini 17G aspiration needle (Gallini,
Mantova, Italy). Safety controls included the determination
of haemoglobin 4 hours after biopsy.
For laparoscopy a pneumoperitoneum was created by
N2O insuﬄation via a Veress needle in general to the left
and lateral of the umbilicus. A second access was obtained
on the right side by inserting a second trocar. A 16G true cut
needle(BIPGmbH,Tuerkenfeld,Germany)wasinsertedand
biopsies of the liver were taken from the left and right lobes
under vision. Biopsy sites were prophylactically coagulated.Gastroenterology Research and Practice 3
Table 1: Distribution of diﬀerent patient groups to liver biopsy
methods applied.
Indication TJLB PLB LLB
Indeterminate liver disease (n) 45 (44%) 32 (32%) 38 (34%)
Acute/subacute liver failure (n) 32 (31%) 1 (1%) 0 (0%)
Chronic hepatitis 12 (12%) 43 (43%) 24 (21%)
LFT elevation after OLT (n) 11 (11%) 19 (19%) 0 (0%)
Others (n) 2 (2%) 5 (5%) 50 (45%)
Total (n) 102 100 112
2.2. Statistics. Data obtained from the patient charts were
analyzed using the software Statview Version 5.0.1. The
various groups were compared using χ2-test, correlation z-
test or Student’s t- t e s ta sa p p r o p r i a t e .AP-value below .05
was considered signiﬁcant.
3. Results
3.1. Transjugular Liver Biopsy Patients. 101 patients under-
went 102 TJLB. Forty ﬁve (45%) patients were female; the
median age was 47 years (range 16–75). Contraindications
for PLB that led to TJLB were coagulopathy (n = 42/41%),
ascites (n = 33/32%), or combined ascites and coagulopathy
(n = 27/27%). Indications for liver biopsy were a diagnostic
work up for indeterminate liver disease (n = 45/44%),
acute/subacute liver failure (n = 32/31%), staging/grading
of chronic hepatitis (all: n = 12/12%, hepatitis C [HCV]:
n = 6/5.9%, hepatitis B [HBV]: n = 3/2.9%, autoimmune
hepatitis [AIH]: n = 3/2.9%), diagnostic work up of OLT
patients with elevated LFTs (n = 11/10.8%), and others
(n = 2/2%, PBC/malignant tumour) (Table 1).
3.2.PercutaneousLiverBiopsyPatients. Onehundredconsec-
utive PLBs in 100 patients were evaluated. The median age
was 47 years (range 18–77). Females and males were equally
distributed (50 female, 50 male). Indications for performing
PLBwereadiagnosticworkupforindeterminateliverdisease
(n = 32/32%), staging/grading of chronic hepatitis (all: n =
43/43%, HCV: n = 26/26%, HBV: n = 12/12%, AIH: n =
5/5%), a diagnostic work up of OLT patients with elevated
LFTs (n = 19/19%), acute/subacute liver failure (n = 1/1%),
and others (all: n = 5/5%, primary sclerosing cholangitis
[PSC]:n = 2/2%,primarybiliarycirrhosis[PBC]:n = 2/2%,
alpha-1 antitrypsin deﬁciency: n = 1/1%) (Table 1).
3.3.LaparoscopicLiverBiopsyPatients. mLLBwasperformed
in 112 patients. The median age was 46 years (range 17–
75). 49 (44%) of the patients were women. Fifteen patients
fulﬁlled contraindication criteria for PLB (n = 13/12%
ascites, n = 2/2% ascites and coagulopathy). Indications
for performing mLLB were a diagnostic work up for
indeterminate liver disease (n = 38/34%), staging/grading
of chronic hepatitis (all: n = 24/21%, HCV: n = 17/15%,
AIH: n = 5/5%, HBV: n = 2/2%), others (all: n = 50/45%,
PSC: n = 33/30%, PBC: n = 5/5%, malignant tumour: n =
10/9%, alpha-1 antitrypsin deﬁciency: n = 2/2%) (Table 1).
3.4. Technical Success of TJLB. 84 (82%) of 102 TJLB were
successful. In 10 (10%) cases investigators failed to cannulate
a hepatic vein, in 6 (6%) cases the investigators could not
pass the right atrium, cannulate the jugular vein, or access
the superior vena cava. In 2 (2%) cases cannulation of the
hepatic vein was successful, but despite repeated attempts no
suﬃcient biopsy material could be obtained.
Cannulation of the hepatic vein failed in 2 of the 11
(18%) patients that presented with elevated LFTs after OLT.
In contrast, in the other indication groups the cannulation
of the hepatic veins failed in 9% (n = 4) of patients that
presented diagnostic work up for indeterminate liver disease,
9% (n = 3) of patients with acute/subacute liver failure and
8% (n = 1) of patients with chronic hepatitis. This diﬀerence
was not statistically signiﬁcant (χ2-test; P = .9).
AllPLBsweretechnicallysuccessfuland111of112(99%)
mLLB were technically successful. In one case mLLB failed
due to an obstructed visualization of the liver surface
The technical success rate was signiﬁcantly lower in TJLB
(82%) than in PLB or mLLB (χ2-test; P = .0005).
3.5. Complications. In the TJLB group no major complica-
tions according to SIR (Society of Interventional Radiology)
guidelines were observed [13]. In one case, an intrainter-
ventional rupture of the liver capsule was suspected, which
was not conﬁrmed during the subsequent clinical course.
In another case, the carotid artery had been accidentally
punctured. However, no further bleeding or infectious
complications occurred. In one case, injection of contrast
agent to conﬁrm the correct position of the introducer
set resulted in formation of a radiopaque depot without
further consequences. In total, this corresponds to a minor
complication rate of 2.9%.
The complication rate of the PLB was 3% In one case,
the patient developed a vasovagal syncope treated with ﬂuid
substitution. Furthermore, we observed one case of severe
postinterventional pain that required treatment with opioid
analgetics and one case with a drop in hemoglobin in the 4
hours postinterventional control. No substitution of blood
products was required.
After mLLB complications were observed in 3 patients
(2.7%). One was a major complication with postinter-
ventional bleeding that required substitution with blood
products.Theothertwocomplicationswereminorincluding
a biliary leak and minor bleeding from the biopsy location.
Both could be handled with coagulation during the inter-
vention. No substitution with blood products was required
in this case.
3.6. Quality of Biopsy Specimens. With TJLB a median of 2
biopsies (range 1–7), with PLB a median of 1 biopsy (range
1-2),andwithmLLBamedianof2biopsies(range1–7)were
taken.
On average, 4.3±0.3 complete portal tracts (range 0–
12) were identiﬁed in TJLB samples (Figure 1). In 14 (16%)
cases, biopsies were judged as inappropriate for complete
evaluation in the pathology report (indeterminate liver
disease [n = 10], LFT elevation after OLT [n = 2], chronic
hepatitis [n = 1], others [n = 1]). These specimens had4 Gastroenterology Research and Practice
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Figure 1: Biopsy quality. Signiﬁcantly more portal tracts were
detected in PLB and MLLB if compared to TJLB.
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Figure2:Indeterminateliverdisease.Blackbarsshowthepercentage
of cases in which the etiology of liver disease was identiﬁed during
the clinical course. The white bars show the percentage of cases in
which liver biopsy contributed substantially to the establishment of
the diagnosis. No diﬀerence was found between the rate of TJLB,
PLB and mLLB.
an average of only 1.6±0.4 (range 0–5) detectable complete
portal tracts.
A calculated mean of 11.7±0.5 and of 11.0±0.6 com-
plete portal tracts was found in PLB and mLLB, respectively
(Figure 1). In 4 cases of both PLB and mLLB biopsy spec-
imens were inappropriate for complete evaluation. These
biopsies contained a mean of 3.9±0.8 and 7.5±1.3 portal
tracts.
With regard to number of portal tracts (P<. 0001,
Student’s t-test; see Figure 1) and the appropriateness for
histological evaluation (P<. 05, χ2-test), the quality of the
TJLB samples was signiﬁcantly lower compared to that PLB
and mLLB.
3.7.IndeterminateLiverDisease. Oneofthemainindications
for a liver biopsy in liver disease of unknown etiology is
to establish a diagnosis allowing an appropriate therapy.
Furthermore, biopsy may reveal prognostic information
(e.g., ﬁbrosis versus cirrhosis).
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Figure 3: Hepatocellular necrosis in acute/subacute liver failure.
More than 25% of hepatocellular necrosis was associated with a
poor transplant free survival.
In the TJLB group, speciﬁcation of the underlying liver
disease was possible in 57% (n = 20/35) of patients during
the clinical course. In 54% the TJLB was relevant to the
establishment of the diagnosis (Figure 2).
InthePLBgroupaspeciﬁcationofdiseasewasreachedin
78% (n = 25) and PLB contributed to the diagnosis in 75%
(n = 24) of patients with etiologically unclear liver disease
(n = 32), while in the mLLB group (n = 38) a speciﬁcation
was successful in 58% (n = 22) and histology contributed in
all cases (n = 22) (Figure 2).
Statistical analysis revealed no signiﬁcant diﬀerence
between the three groups in respect to speciﬁcation and the
impact of the histology (χ2-test, Figure 2).
3.8. Acute/Subacute Liver Failure. The underlying disease
couldbeclariﬁedin51%(n=15)ofpatientswhounderwent
TJLB for acute/subacute liver failure. No necrosis was found
in 7 cases, low grade (1%–25%) necrosis was detected in
6, medium grade (26%–50%) necrosis was detected in 10,
severe (51%–75%) in 5, and complete necrosis (76%–100%)
was found in 1 case. Spontaneous recovery was observed
in 83% of patients with 0%–25% necrosis, while only 31%
of patients that had more than 25% of necrosis survived
without liver transplantation. In general, higher grades of
necrosiswereassociatedwithasigniﬁcantlylowerproportion
of transplant free survival (χ2-test, P<. 036) (Figure 3).
In 22 (69%) of the cases with acute/subacute liver failure
the underlying disease could be clariﬁed during the clinical
course. We found steatohepatitis in 5, malignant tumour in
n = 3, viral hepatitis n = 3, autoimmune hepatitis in n = 4,
Wilson’s disease in n = 1, hemochromatosis in n = 1, and
toxic reaction in n = 5c a s e s .I nn = 15 (52%) the TJLB
was relevant to the establishment of the diagnosis. A speciﬁcGastroenterology Research and Practice 5
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Figure 4: Staging/grading in chronic hepatitis.N os t a t i s t i c a l l y
signiﬁcant diﬀerence in the rate of staging/grading for chronic
hepatitis was detected between the three groups.
therapy was started in n = 6 (19%) of patients. Interestingly,
TJLB contributed to the diagnosis in all these cases.
Unfortunately, we could not generate a suﬃcient control
group for acute/subacute liver failure from the PLB (n = 1)
and mLLB (n = 0) groups.
3.9. Chronic Hepatitis. To guide antiviral and immunosup-
pressivetherapyinchronichepatitisanadequategradingand
staging is essential. The biopsy specimen was appropriate for
scoringin88%(n = 7)ofpatientswithchronichepatitisthat
underwent TJLB (Figure 4).
In the chronic hepatitis group, suﬃcient scoring was
possible with PLB in 98% (n = 42) and with mLLB in 100%
(n = 24, Figure 4).
We did not ﬁnd a signiﬁcant diﬀerence between the three
groups (χ2-test; P = .156). However, the low number of
patients in the TJLB group (n = 8) should be noted.
3.10. Diagnostic Work up of Liver Transplant Patients with
Elevated LFTs. Histological analysis in this patient group
using TJLB revealed cholestasis (n = 3), hepatitis (n = 1),
ischemia associated alteration (n = 1), chronic rejection
(n = 1), or unspeciﬁed alterations (n = 2). In all cases
histological results were important for clinical management
as histology ruled out acute rejection in all cases. Due to
adhesions no mLLB was performed in this patient group.
3.11. Discussion. In our patient cohort, TJLB was associated
with a low minor complication rate of 2.9%. No major
complicationsoccurred.IncomparisonwithPLBandmLLB,
no signiﬁcant diﬀerence in intervention associated risks
was observed despite signiﬁcant coagulopathy in 68% of
the patients that underwent TJLB. In this regard, our
data are comparable to the complication rates reported by
other groups. In their systematic review of 64 publications
including 7649TJLBs, Kalambokis et al. observed minor
complications in 6.5% and major complications in 0.56%
of patients [5]. Therefore, despite the signiﬁcantly impaired
liver function, in most cases TJLB can clearly be considered a
low-risk intervention.
However, our data analysis also showed a high rate of
technical failure in the TJLB group. With only 82% technical
successwewerelesseﬀectivethanothergroupswithreported
technical success rates between 87% and 100% also using
a true cut biopsy set as in our clinic. The reason for this
high rate of technical failure especially the high rate of failed
cannulationofthehepaticveinisnotclear.Wesuspectedthat
the high rate of transplant patients and their altered vascular
anatomy may have inﬂuenced the outcome in our study
[14]. Indeed, the cannulation of a hepatic vein failed more
often in patients that underwent liver transplantation than
in the other patient groups. However, this diﬀerence was not
statistically signiﬁcant. Furthermore, other groups recently
reported no technical problems with TJLB in transplant
patients [15, 16]. Another reason may be the low annual rate
of 15TJLBs/year performed at our hospital in comparison
with other groups that reported annual rates between 48 and
111 [17]. In parallel to our evaluation Soyer et al. recently
suggested the use of ultrasonographic guidance [18]. Since
2006, we consequently applied ultrasonographic guidance
for jugular vein puncture for TJLB. Fortunately, no technical
failures have occurred from 04/2006 until today at our
institution.
A liver biopsy cylinder of ≥15mm length containing
6–10 complete portal tracts is regarded suﬃcient for the
histological diagnosis of diﬀuse liver diseases [1, 19, 20],
whereas 20mm and/or 11 portal ﬁelds are regarded as
minimum for a meaningful grading and staging in chronic
hepatitis [21, 22]. It was therefore not surprising that the
quality of TJLB turned out to be signiﬁcantly lower than
biopsies generated from PLB or mLLB if judged by the
pathologist’s evaluation and the number of portal tracts.
We found a mean of 4.3 ±0.3 complete portal tracts in our
TJLB samples. In their analysis, Kalambokis et al. reported
a mean of 6.8 complete portal tracts [5]. However, despite
the signiﬁcantly lower number of complete portal tracts in
comparison with PLB and mLLB, we were not able to ﬁnd a
diﬀerence in terms of staging/grading for chronic hepatitis.
Furthermore, in the indeterminate liver disease group the
proportion of cases in which a liver biopsy contributed
to the establishment of a diagnosis was not signiﬁcantly
diﬀerent between TJLB, PLB and mLLB. However, it has to
be emphasized that the contribution of a biopsy sample to
the establishment of a diagnosis is diﬃcult to evaluate and
therefore the statistical analysis has to be judged carefully.
Furthermore, understaging and sampling error resulting
from small biopsy cylinders cannot be excluded [21]. In
addition the low success rate of TJLB in our cohort is
anotherdisadvantageandmightaﬀecttheabilityofdiagnosis
using TJLB. Therefore, we feel that especially in patients
with ascites mLLB is a valuable alternative to TJLB. Our
study shows that biopsies generated from mLLB are of
signiﬁcantly better quality. In addition, visualization of the
liver surface in mLLB gives additional information and
avoids sampling errors [4, 23]. So far, only few data have
been reported evaluating mLLB as an alternative to TJLB
in patients with severe coagulopathy [11]. If mLLB is not
available a minimum of three needle passes with TJLB
should be performed to obtain optimal tissue samples [24].6 Gastroenterology Research and Practice
Cholongitas et al. did not ﬁnd a diﬀerence in the number
of portal tracts if at least three needle passes were applied in
comparison with PLB using a Menghini needle [15, 24]. This
group even suggested four needle passes in their most recent
publication [25].
Acute/subacute liver failure is a dramatic and potentially
fatal condition characterized by severely impaired liver func-
tion with jaundice, coagulopathy and encephalopathy. The
underlying etiologies include toxic, infectious, autoimmune,
and metabolic etiologies. Therefore, a timely diagnosis
needs to be established to begin speciﬁc therapy whenever
indicated or to evaluate emergency liver transplantation.
Variables that have been used to predict prognosis are
hepatic encephalopathy, serum bilirubin, and coagulopathy.
Furthermore scores such as the King’s College criteria have
been established to estimate the prognosis in patients with
acute liver failure [26]. Liver histology may be supportive
in this clinical situation because it can estimate the grade
of necrosis and hopefully the regenerative activity. However,
the severe coagulopathy associated with acute liver failure
hinders regular percutaneous liver biopsies in this clinical
setting. Therefore, TJLB is an important diagnostic tool in
acute liver failure with severe coagulopathy. Despite a vast
amount of studies employing TJLB, only two studies have
been published so far that have focussed on the role of TJLB
in acute liver failure [27, 28]. Donaldson and colleagues
retrospectively investigated 60 successful transvenous liver
specimens from patients with acute liver failure. They found
a correlation between degree of hepatocellular necrosis and
survival. Especially a necrosis rate of greater than 70% was
associated with a poor outcome. Miragli et al. prospectively
studied 17 patients who underwent TJLB for acute liver
failure. They showed that TJLB can alter an initial diagnosis
(18% of cases). Furthermore, necrosis of less than 60%
was associated with a better prognosis than submassive or
massive necrosis (≥85%), which resulted in death or liver
transplantation. Our study is the second largest cohort (n =
32) that studied the relevance of TJLB in acute liver failure.
In accordance with the studies by Donaldson et al. and
Miragli et al. we were able to show that higher rates of
hepatocellular necrosis are related to higher rates of death
and/or liver transplantation. A proportion of necrosis of
more than 25% was already associated with a signiﬁcantly
lower rate of organ/patient survival. However, as the degree
of necrosis might have inﬂuenced the decision to perform
liver transplantation, the predictive value of hepatic necrosis
forpatientoutcomeinacuteliverfailurehastobeinterpreted
cautiously.Thefactthatwefoundaslightlybetteroutcomein
the 51%–75% group than in the 26%–50% group (although
statistically not signiﬁcant) may be attributed to a non
avoidable sampling error.
4. Conclusion
We conclude from our retrospective study that liver biopsies
generated via the transjugular approach are indeed valuable
for clinical decisions in various indication groups, although
sample quality may limit the diagnostic power in some
patients. Furthermore, the degree of hepatic parenchymal
necrosis which can be estimated by means of TJLB might
predict outcome in patients with acute/subacute liver failure.
We therefore suggest performing TJLB in patients with acute
liver failure that are possible liver transplant candidates to
estimate prognosis. In accordance with recent studies, a
minimum of four needle passes should be performed to
optimize sample quality.
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